COMPANY:

Danaher Corp

"Swiss life science informatics firm Genedata said Monday that it has been acquired by Danaher for an undisclosed amount...The acquisition is expected to add to Danaher's tools for drug discovery, development, and manufacturing and follows several previous collaborations between the two companies."

"Danaher Corporation...announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs intended to accelerate the development of Companion Diagnostics (CDx) and Complementary Diagnostics (CoDx)."

"Danaher Corporation...announced today it has completed its acquisition of Abcam plc...The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the 'Scheme') and the Scheme became effective in accordance with its terms on December 6, 2023."

"Cepheid announced today that it has received the CE mark for Xpert NPM1 Mutation, a molecular in vitro diagnostic test for the quantification of mutant NPM1 mRNA transcripts (types A, B and D in exon 12) in peripheral blood specimens from patients with Acute Myeloid Leukemia (AML). The test utilizes automated real-time reverse transcription polymerase chain reaction (RT-PCR) and reports the percent ratio of mutant NPM1 to ABL1 endogenous control mRNA transcripts."

"Leica Biosystems today announced the US Food and Drug Administration (FDA) 510(k) clearance of the BOND MMR Antibody Panel, providing customers with a high-performing IHC Mismatch Repair (MMR) option when screening colorectal cancer patients for the identification of probable Lynch syndrome."

"University College Dublin (UCD) today formally announced the acquisition of OncoMark Ltd, a UCD spin-out company, by US molecular diagnostics company, Cepheid Inc...OncoMark Ltd developed the OncoMasTR test, based on a panel of genetic drivers of breast cancer."